Zura Bio Relocates Principal Executive Offices to Henderson, NV

TL;DR

**Zura Bio moved its main office to Henderson, NV, effective January 3, 2024.**

AI Summary

Zura Bio Ltd. filed an 8-K on January 8, 2024, reporting a change in its principal executive offices from La Jolla, CA to 1489 W. Warm Springs Rd. #110, Henderson, Nevada 89014, effective January 3, 2024. This move could signal a strategic shift in operations or a cost-saving measure, which might impact the company's operational efficiency and future growth prospects, making it relevant for investors to monitor for potential implications on the stock's long-term value.

Why It Matters

A change in headquarters can reflect strategic shifts, cost-cutting efforts, or expansion plans, all of which can influence a company's operational efficiency and investor perception.

Risk Assessment

Risk Level: low — A change in business address is generally a minor administrative event with low direct risk to investors.

Analyst Insight

Investors should monitor future filings or company announcements for the reasons behind the relocation, as it could indicate broader strategic changes or cost-saving initiatives that might impact the company's financial health.

Key Players & Entities

• Zura Bio Ltd. (company) — the registrant filing the 8-K
• January 3, 2024 (date) — date of earliest event reported
• January 8, 2024 (date) — date the 8-K was filed
• 1489 W. Warm Springs Rd. #110, Henderson, Nevada 89014 (location) — new principal executive offices
• 4225 EXECUTIVE SQUARE, SUITE 600, LA JOLLA, CA 92037 (location) — former business address

Forward-Looking Statements

• Zura Bio Ltd. will experience minor operational disruptions due to the office relocation. (Zura Bio Ltd.) — low confidence, target: 2024-03-31

FAQ

Key Financial Figures

• $0.0001 — ed Class A Ordinary Shares, par value $0.0001 per share ZURA The Nasdaq Stock Mar
• $11.50 — Ordinary Share at an exercise price of $11.50 per share ZURAW The Nasdaq Stock Ma
• $6.7 billion — ceutical company acquired by Pfizer for $6.7 billion in 2022. At Arena, Mr. Robert Lisicki h
• $8.0 billion — acquisitions activities totaling nearly $8.0 billion. Prior to Arena, Mr. Robert Lisicki ser
• $440,000 — i will be paid an annual base salary of $440,000. Following the end of each calendar yea

Filing Documents

• tm242343d1_8k.htm (8-K) — 40KB
• tm242343d1_ex10-1.htm (EX-10.1) — 59KB
• tm242343d1_ex99-1.htm (EX-99.1) — 16KB
• tm242343d1_ex99-1img01.jpg (GRAPHIC) — 10KB
• 0001104659-24-001984.txt ( ) — 366KB
• zura-20240103.xsd (EX-101.SCH) — 3KB
• zura-20240103_def.xml (EX-101.DEF) — 26KB
• zura-20240103_lab.xml (EX-101.LAB) — 36KB
• zura-20240103_pre.xml (EX-101.PRE) — 25KB
• tm242343d1_8k_htm.xml (XML) — 5KB

02

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Chief Medical Officer and Executive Vice President. On January 4, 2024, Dr. Chris Cabell and Zura Bio Limited (the "Company") agreed that he will be stepping down as the Company's Chief Medical Officer and Executive Vice President, effective on January 15, 2024. Dr. Chris Cabell's resignation was not the result of any disagreement with management or the Company on any matter relating to the Company's operations, policies or practices. Appointment of President and Chief Operating Officer. On January 3, 2024, the Company appointed Mr. Robert Lisicki as President and Chief Operating Officer, effective as of January 8, 2024 (the "Commencement Date"). Mr. Robert Lisicki, age 56, is an experienced executive leader with a career spanning nearly 30 years in the biopharmaceutical industry. Mr. Robert Lisicki has been serving on the boards of Adiso Therapeutics and Cadrenal Therapeutics, Inc. since October 2023 and July 2023, respectively. He served as the Chief Commercial Officer at Arena Pharmaceuticals from October 2018 to March 2022, a prominent biopharmaceutical company acquired by Pfizer for $6.7 billion in 2022. At Arena, Mr. Robert Lisicki had accountability for building the company's global commercial infrastructure and contributed to its mergers and acquisitions activities totaling nearly $8.0 billion. Prior to Arena, Mr. Robert Lisicki served as Vice President and General Manager of Inflammation and Cardiovascular at Regeneron Pharmaceuticals. In this dual role, he led both commercial and developmental initiatives. His career also includes senior leadership roles as CEO and Board Member, InCarda Therapeutics; CCO, Daiichi Sankyo, Inc.; and VP, Amgen, with his initial experience in sales and marketing at The Janssen Pharmaceutical Companies of Johnson & Johnson. He holds a Bachelor of Scie

01

Item 7.01. Regulation FD Disclosure. On January 8, 2024, Zura Bio Limited issued the press release attached hereto as Exhibit 99.1 to this Current Report on Form 8-K. The information set forth in this Item 7.01 is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1+ Employment Agreement between Zura Bio Limited and Robert Lisicki 99.1 Press Release dated January 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) + Indicates management contract or compensatory plan.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 8, 2024 ZURA BIO LIMITED By: /s/ Kim Davis Name: Kim Davis Title: Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR